BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25642915)

  • 1. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach.
    Werner RA; Bluemel C; Lassmann M; Kudlich T; Higuchi T; Lopci E; Allen-Auerbach M; Colletti PM; Rubello D; Zatelli MC; Herrmann K
    Clin Nucl Med; 2015 May; 40(5):e271-7. PubMed ID: 25642915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic in Nuclear Medicine - The paradigm of NET.
    Giammarile F
    Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
    Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
    AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
    Kjaer A; Knigge U
    Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear medicine procedures in the diagnosis of NET: a historical perspective.
    Maffione AM; Karunanithi S; Kumar R; Rubello D; Alavi A
    PET Clin; 2014 Jan; 9(1):1-9. PubMed ID: 25029929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
    Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
    Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical studies of SPECT and PET tracers for NET.
    Brom M; Boerman O; Gotthardt M; Oyen WJ
    PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
    Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
    Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
    Pepe G; Bombardieri E; Lorenzoni A; Chiti A
    PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
    Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K
    Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.